How many stocks are there of GenKyoTex?
The current number of stocks of GenKyoTex is 11.79 M undefined.
GenKyoTex Stocks 2024
GenKyoTex Stocks
11.79 M
Ticker
GKTX.PA
ISIN
FR0013399474
WKN
A2PE0M
In 2024, GenKyoTex had 11.79 M outstanding stocks, a 0% change from the 11.79 M stocks in the previous year.
The GenKyoTex Stocks history
| YEAR | NUMBER OF STOCKS (undefined ) |
|---|---|
| 2024e | 11.79 |
| 2023e | 11.79 |
| 2022e | 11.79 |
| 2021e | 11.79 |
| 2020 | 11.79 |
| 2019 | 8.55 |
| 2018 | 8.19 |
| 2017 | 6.93 |
| 2016 | 0.27 |
| 2015 | 1.62 |
| 2014 | 1.39 |
| 2013 | 0.95 |
| 2012 | 0.7 |
| 2011 | 0.7 |
GenKyoTex shares outstanding FR0013399474 · A2PE0M
The number of shares was GenKyoTex in 2023 — This indicates how many shares 11.787 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue GenKyoTex earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates GenKyoTex's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of GenKyoTex’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating GenKyoTex's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2011 | 700,000 Aktien |
| 2012 | 700,000 Aktien |
| 2013 | 950,000 Aktien |
| 2014 | 1.39 M Aktien |
| 2015 | 1.62 M Aktien |
| 2016 | 266,220 Aktien |
| 2017 | 6.93 M Aktien |
| 2018 | 8.19 M Aktien |
| 2019 | 8.55 M Aktien |
| 2020 | 11.79 M Aktien |
| 2021e | 11.79 M Aktien |
| 2022e | 11.79 M Aktien |
| 2023e | 11.79 M Aktien |
| 2024e | 11.79 M Aktien |
GenKyoTex Aktienanalyse
What does GenKyoTex do?
GenKyoTex SA is a Swiss biotechnology company specializing in the development of innovative therapies for the treatment of inflammatory diseases. The company was founded in 2006 by Dr. Elias Papatheodorou and Dr. Takashi Mizuno and is headquartered near Lausanne. The history of GenKyoTex SA began with the discovery of a new enzyme called NOX (NADPH oxidase) 1/4, which plays a crucial role in the onset of inflammation. This was the starting point for the development of inhibitors that reduce NOX activity and thus halt the progression of inflammatory diseases such as fibrosis, arthritis, or kidney failure. GenKyoTex SA's business model is based on the development and marketing of therapeutics based on NOX inhibitor technology. The company works closely with leading experts and research institutions to develop innovative drugs and conduct clinical trials. The different divisions of GenKyoTex SA include expertise in formulation, manufacturing, and stabilization of active ingredients and drugs, as well as the development of clinical trials and optimization of production processes. The company has its own research and development department, allowing it to oversee the entire value chain associated with its products. The company has developed a range of products based on NOX inhibitor technology. One of these is GKT831, a drug used to treat patients with idiopathic pulmonary fibrosis (IPF). IPF is a chronic and progressive condition in which lung tissue becomes inflamed and scarred, impairing oxygen uptake. GKT831 has shown promising results in a clinical program. Another product from GenKyoTex SA is GKT771, a drug used to treat patients with diabetic nephropathy. Diabetic nephropathy is a complication of diabetes in which kidney function deteriorates. GKT771 has shown positive results in a phase 2 study and is now in phase 3 development. Overall, GenKyoTex SA is an innovative company focused on the development of drugs for the treatment of inflammation. The company has expertise in NOX inhibitor technology and has already brought several promising products to market or in development. Thanks to collaboration with leading experts and research institutions, GenKyoTex SA can accelerate the development of new drugs and improve patients' quality of life. GenKyoTex ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating GenKyoTex's Shares Outstanding
GenKyoTex's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in GenKyoTex’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding GenKyoTex’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in GenKyoTex’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about GenKyoTex stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of GenKyoTex are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of GenKyoTex evolved in recent years?
The number of shares of GenKyoTex has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. GenKyoTex as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of GenKyoTex?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does GenKyoTex pay?
Over the past 12 months, GenKyoTex paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, GenKyoTex is expected to pay a dividend of 0 .
What is the dividend yield of GenKyoTex?
The current dividend yield of GenKyoTex is .
When does GenKyoTex pay dividends?
GenKyoTex pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of GenKyoTex?
GenKyoTex paid dividends every year for the past 0 years.
What is the dividend of GenKyoTex?
For the upcoming 12 months, dividends amounting to 0 are expected. This corresponds to a dividend yield of 0 %.
In which sector is GenKyoTex located?
GenKyoTex is assigned to the 'Health' sector.
Wann musste ich die Aktien von GenKyoTex kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of GenKyoTex from 8/28/2024 amounting to 0 , you needed to have the stock in your portfolio before the ex-date on 8/28/2024.
When did GenKyoTex pay the last dividend?
The last dividend was paid out on 8/28/2024.
What was the dividend of GenKyoTex in the year 2023?
In the year 2023, GenKyoTex distributed 0 as dividends.
In which currency does GenKyoTex pay out the dividend?
The dividends of GenKyoTex are distributed in .
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von GenKyoTex
Our stock analysis for GenKyoTex Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GenKyoTex Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
